Electromed, Inc. (ELMD) is a recognized leader in the respiratory healthcare industry specializing in the design, marketing, and distribution of State-of-the-art airway clearance products. Established in 1992 and headquartered in New Prague, Minnesota, the company operates with a dual focus on enhancing the quality of life for patients with compromised pulmonary function and minimizing hospitalizations resulting from recurring lung infections.
Their flagship product, the SmartVest Airway Clearance System, is a multifaceted product distinguished for its innovative technology that efficiently simplifies therapy in a patient-friendly manner. The unique system leverages High Frequency Chest Wall Oscillation (HFCWO) technology that is designed to dislodge mucus from bronchial walls, and mobilize secretions and mucus from the lungs. This ultimately enhances airway clearance, reducing the risk of respiratory infections and improving lung function over time. Notably, SmartVest is the only HFCWO device with a proven randomized, controlled clinical study demonstrating a significant reduction in exacerbation and antibiotic use.
Apart from manufacturing stellar products, Electromed is also noted for its dedication to providing comprehensive, personalized support to their customers, physicians, and therapists, thereby enhancing successful management of respiratory health. From education and training, to insurance authorizations and ongoing support through the SmartVest Connect portal, Electromed employs a patient-centric approach that seeks to ensure support at every step of the journey.
Furthermore, the company marked its place on the NASDAQ in 2010 and continues to meet the stringent NASDAQ standards, signifying their financial stability and growth orientation. This achievement underscores the company's unwavering commitment to providing top-notch respiratory products and services, and the appreciation it has garnered in both the patient community and the industry.
In tandem with their mission, Electromed, Inc. continues to invest in research and development, propelling advancements in product and service offerings. Reflecting their commitment to meet the ever-changing needs of the respiratory healthcare sector, the company seeks to maintain an agile and dynamic presence that aligns with the demands of patients and healthcare providers alike.
In summary, Electromed, Inc. stands as a vanguard entity in the healthcare industry, bringing about better living for people with respiratory conditions and contributing value to the healthcare system through its effective, innovative solutions in airway clearance therapy.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Electromed (AMEX: ELMD) reported record Q4 EPS of $0.39, exceeding estimates by 21.88%, with quarterly sales rising 11.6% year-over-year to $19.4 million. For the full fiscal year 2026, revenue grew 15.3% to $73.0 million, and diluted EPS reached $1.30. Additionally, CEO Jim Cunniff announced his planned retirement for April 2027, with a succession plan underway.
Electromed Inc. reported record Q4 2026 net revenue of $19.4 million, a 12% increase year-over-year, and operating income growth of 26% to $3.8 million. The company expanded its direct sales force and announced CEO Jim Cunniff's planned retirement in April 2027, with a succession plan in place. Electromed achieved 78.5% gross margin for fiscal 2026 and 15.3% annual revenue growth to $73 million, driven by its core home care channel and strategic initiatives like the "Triple Down on Bronchiectasis" campaign.
Electromed, Inc. (ELMD) reported Q4 earnings of $0.39 per share, exceeding the Zacks Consensus Estimate of $0.32, marking a 21.88% surprise. The company's revenues for the quarter were $19.42 million, slightly missing the consensus estimate. Electromed's stock has seen a significant increase of 38.4% year-to-date, outperforming the S&P 500, and currently holds a Zacks Rank #3 (Hold).
Renaissance Technologies LLC decreased its stake in Electromed, Inc. (NYSE:ELMD) by 28.3% in the first quarter, selling 49,000 shares but still retaining 124,004 shares valued at $2.9 million. Other institutional investors like Millennium Management LLC and Geode Capital Management LLC increased their holdings. Insider selling by the CFO and CEO also occurred, totaling over $2.2 million in the last 90 days, while analysts maintain a "Moderate Buy" consensus with an average price target of $37.50.